Stocks & Investing
Fri, September 10, 2021
[ Fri, Sep 10th 2021
] - WOPRAI
Thu, July 8, 2021
[ Thu, Jul 08th 2021
] - WOPRAI
Wed, March 31, 2021
[ Wed, Mar 31st 2021
] - WOPRAI
[ Wed, Mar 31st 2021
] - WOPRAI
Thu, November 5, 2020
[ Thu, Nov 05th 2020
] - WOPRAI
Thu, August 6, 2020
[ Thu, Aug 06th 2020
] - WOPRAI
Fri, June 5, 2020
[ Fri, Jun 05th 2020
] - WOPRAI
Tue, May 12, 2020
[ Tue, May 12th 2020
] - WOPRAI
Tue, March 31, 2020
[ Tue, Mar 31st 2020
] - WOPRAI
Tue, December 3, 2019
[ Tue, Dec 03rd 2019
] - WOPRAI
Thu, September 12, 2019
[ Thu, Sep 12th 2019
] - WOPRAI
Mon, June 17, 2019
[ Mon, Jun 17th 2019
] - WOPRAI
Thu, May 3, 2018
[ Thu, May 03rd 2018
] - WOPRAI
Thu, February 22, 2018
[ Thu, Feb 22nd 2018
] - WOPRAI
Tue, December 5, 2017
[ Tue, Dec 05th 2017
] - WOPRAI
Mon, October 30, 2017
[ Mon, Oct 30th 2017
] - WOPRAI
Tue, June 6, 2017
[ Tue, Jun 06th 2017
] - WOPRAI
Fri, November 11, 2016
[ Fri, Nov 11th 2016
] - WOPRAI
Mon, June 15, 2015
[ Mon, Jun 15th 2015
] - WOPRAI
Thu, April 23, 2015
[ Thu, Apr 23rd 2015
] - WOPRAI
Matthew Luchini Maintained (APLS) at Buy with Decreased Target to $69 on, Sep 10th, 2021
Matthew Luchini of BMO Capital, Maintained "Apellis Pharmaceuticals, Inc." (APLS) at Buy with Decreased Target from $89 to $69 on, Sep 10th, 2021.
Matthew has made no other calls on APLS in the last 4 months.
There are 4 other peers that have a rating on APLS. Out of the 4 peers that are also analyzing APLS, 0 agree with Matthew's Rating of Hold.
These are the ratings of the 4 analyists that currently disagree with Matthew
- Chris Howerton of "Jefferies" Initiated at Strong Buy and Held Target at $74 on, Thursday, August 19th, 2021
- Steven Seedhouse of "Raymond James" Maintained at Strong Buy with Decreased Target to $102 on, Tuesday, August 10th, 2021
- Anupam Rama of "JP Morgan" Maintained at Buy with Increased Target to $101 on, Friday, July 2nd, 2021
- Eliana Merle of "UBS" Initiated at Strong Buy and Held Target at $82 on, Friday, May 21st, 2021
